Highest-materiality recent filing
Anavex files proxy for Sep 24 meeting, adds two independent directors amid PVG proxy fight
2026 annual meeting set for Sep 24, 2026; record date Jul 31, 2026; PVG owns 0.35% of shares.
Anavex Life Sciences Announces Board Refresh, Nominates Two New Independent Directors
Nominates Gautam Patel and Dr. Adrian Senderowicz as new independent director candidates for 2026 Annual Meeting.
Anavex reports preliminary Q2 FY2026 net loss of $5.3M; cash $127.4M; focuses on FDA for Alzheimer's
Preliminary net loss $5.3M ($0.06/share) vs $11.2M ($0.13/share) in Q2 2025; R&D expenses down to $4.2M from $9.9M.
Anavex terminates CEO Christopher Missling for cause; appoints Terrie Kellmeyer as interim CEO
Christopher Missling terminated as CEO for cause effective April 30, 2026; Board requested his resignation.
Withdrew EU marketing authorization application for blarcamesine as add-on therapy for early Alzheimer's disease.
Anavex reports Q1 FY2026 net loss $5.7M; EU blarcamesine setback, re-examination ongoing
Net loss of $5.7M ($0.06 per share) vs. $12.1M ($0.14) in Q1 FY2025; R&D expenses dropped to $4.7M from $10.4M.
Net loss for Q4 fiscal 2025 was $9.8M ($0.11 per share), compared to net loss of $11.6M ($0.14) in Q4 fiscal 2024.
Anavex receives negative CHMP trend vote on blarcamesine MAA; plans re-examination
CHMP issued negative trend vote on MAA for blarcamesine for early Alzheimer's; formal opinion expected December 2025.
Anavex Life Sciences enters $150M at-the-market equity facility with TD Securities
Sales agreement with TD Securities (USA) LLC for ATM offering of up to $150M in common stock.
Anavex shareholders OK plan amendment to add 4M shares, enforce one-year vesting
Amendment to 2022 Omnibus Incentive Plan increases authorized shares from 10M to 14M.
Anavex Q2 FY2024 net loss $10.5M, cash $139.4M; blarcamesine EMA submission underway
Net loss of $10.5M ($0.13/share) vs $13.1M loss ($0.17/share) in prior-year quarter.
Anavex confirms no exposure to Silicon Valley Bank deposits or accounts
Company holds no deposits, securities, or accounts at Silicon Valley Bank.
Trial met primary endpoints ADAS-Cog and ADCS-ADL with statistically significant results (p=0.033 and p=0.0255).
CEO Christopher Missling's employment agreement extended to July 5, 2025.
Anavex clarifies AVATAR Phase 3 trial endpoints; plans FDA meeting for Rett syndrome approval
Anavex clarifies that the January 2022 clinicaltrials.gov update was not real-time and does not reflect late endpoint/phase changes.
On May 11, 2026, Felix Lauscher, who had held the title of Chief Operating Officer of Anavex Life Sciences Corp. (the “Company”) since March 1, 2026, departed from the Company as part of a broader reorganization of duties at the Company following the appointment of Dr. Terrie Kellmeyer as the Company’s Interim Chief Executive Officer.
On May 4, 2026, the Board appointed Terrie Kellmeyer, PhD as the Company's Interim Chief Executive Officer.
On April 30, 2026, a special committee (the "Special Committee") composed of independent directors of the Board of Directors (the "Board") of Anavex Life Sciences Corp. (the "Company") terminated the employment of Christopher Missling, PhD as the Company's Chief Executive Officer for Cause (as defined in the Employment Agreement, dated as of June 27, 2013, between Dr. Missling and the Company, as amended and restated), effective immediately, for, among other things, conduct that the Special Committee believed was inconsistent with Company policy.
Max materiality 0.90 · Median 0.55 · Most common event other_material